AU5114499A - Ophthalmic compositions for treating ocular hypertension - Google Patents

Ophthalmic compositions for treating ocular hypertension Download PDF

Info

Publication number
AU5114499A
AU5114499A AU51144/99A AU5114499A AU5114499A AU 5114499 A AU5114499 A AU 5114499A AU 51144/99 A AU51144/99 A AU 51144/99A AU 5114499 A AU5114499 A AU 5114499A AU 5114499 A AU5114499 A AU 5114499A
Authority
AU
Australia
Prior art keywords
formulation
prostaglandin
dihydro
carbonic anhydrase
ophthalmologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU51144/99A
Inventor
Gerald S. Ponticello
Michael F Sugrue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US11995198A priority Critical
Priority to US09119951 priority
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to PCT/US1999/016374 priority patent/WO2000004899A1/en
Publication of AU5114499A publication Critical patent/AU5114499A/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. chlothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Description

WO 00/04899 PCT/US99/16374 TITLE OF THE INVENTION OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION 5 BACKGROUND OF THE INVENTION Glaucoma is a degenerative disease of the eye wherein the intraocular pressure is too high to permit normal eye function. As a result, damage may occur to the optic nerve head and result in 10 irreversible loss of visual function. If untreated, glaucoma may eventually lead to blindness. Ocular hypertension, i.e., the condition of elevated intraocular pressure without optic nerve head damage or characteristic glaucomatous visual field defects, is now believed by the majority of ophthalmologists to represent merely the earliest phase in 15 the onset of glaucoma. Many of the drugs formerly used to treat glaucoma proved not entirely satisfactory. The early methods of treatment of glaucoma employing pilocarpine produced undesirable local effects that made this drug, though valuable, unsatisfactory as a first line drug. More 20 recently, clinicians have noted that many B-adrenergic antagonists are effective in reducing intraocular pressure. While many of these agents are effective for this purpose, there exist some patients with whom this treatment is not effective or not sufficiently effective. Many of these agents also have other characteristics, e.g., membrane stabilizing 25 activity, that become more apparent with increased doses and render them unacceptable for chronic ocular use. Although pilocarpine and B-adrenergic antagonists reduce intraocular pressure, none of these drugs manifests its action by inhibiting the enzyme carbonic anhydrase, and thus they do not take 30 advantage of reducing the contribution to aqueous humor formation made by the carbonic anhydrase pathway. Agents referred to as carbonic anhydrase decrease the formation of aqueous humor by inhibiting the enzyme carbonic anhydrase. While such carbonic anhydrase inhibitors are now used to WO 00/04899 PCT/US99/16374 -2 treat intraocular pressure by systemic routes, they thereby have the distinct disadvantage of inhibiting carbonic anhydrase throughout the entire body. Such a gross disruption of a basic enzyme system is justified only during an acute attack of alarmingly elevated intraocular 5 pressure, or when no other agent is effective. For several years, the desirability of directing the carbonic anhydrase inhibitor to only the desired ocular target tissue has been recognized. Because carbonic anhydrase inhibitors have a profound effect in altering basic physiological processes, the avoidance of a 10 systemic route of administation serves to diminish, if not entirely eliminate, those side effects caused by inhibition of carbonic anhydrase such as metabolic acidosis, vomiting, numbness, tingling, general malaise and the like. Topically effective carbonic anhydrase inhibitors are disclosed in U.S. Patent Nos. 4,386,098; 4,416,890; 4,426,388; 15 4,668,697; and 4,863,922 and 4,797,413. Prostaglandins, or Pgs, are members of a class of organic carboxylic acids that are contained in human and most other mammalian tissues or organs and that exhibit a wide range of physiological activities. Naturally occurring Pgs possess a common structural feature, 20 the prostanoic acid skelton, depicted in Formula I below: 9 7 5 3 (xcan 10 87- COOH (a-chain) 012 14 16 18 20 11

CH

3 (o-chain) 13 15 17 19 Some synthetic analogues have somewhat modified 25 skeletons. The primary PG's are classified based on the structural feature of the five-membered cycle moiety into PGA's, PGB's, PGC's, PGD's PGE's, PGF's PGG's PGH's PGI's and PGJ's and also on the presence or absence of unsaturation and oxidation in the chain moiety as: 30 Subscript 1 13,14-unsaturated-15-OH, WO 00/04899 PCT/US99/16374 -3 Subscript 2 5,6- and 13,14-diunsaturated -15-OH, Subscript 3 5,6-13,14-, and 17,18-triunsaturated 15-OH 5 Further, PGFs are subclassified as a or B according to the configuration of the hydroxy group at position 9. Prostaglandins and prostaglandin derivatives are known to lower intraocular pressure. U.S. Patent 4,883,819 to Bito descibes the use and synthesis of PGAs, PGBs and PGCs in reducing intraocular 10 pressure. U.S. Patent 4,824,857 to Goh et al. describes the use and synthesis of PGD2 and derivatives thereof in lowering intraocular pressure including derivatives wherein C-10 is replaced with nitrogen. U.S. Patent 5,001,153 to Ueno et al. describes the use and synthesis of 13,14-dihydro-15-keto prostaglandins and prostaglandin derivatives to 15 lower intraocular pressure. U.S. Patent 4,599,353 describes the use of eicosanoids and eicosanoid derivatives including prostaglandins and prostaglandin inhibitors in lowering intraocular pressure. Prostaglandin and prostaglandin derivatives lower intraocular pressure by increasing uveoscleral outflow. This is true for 20 both the F type and A type of Pgs and hence presumably also for the B,C,D,E and J types of prostaglandins and derivatives thereof. A problem with using prostaglandin derivatives to lower intraocular pressure is that these compounds often induce an initial increase in intraocular pressure. 25 Since the carbonic anhydrase inhibitor lowers intraocular pressure without accompanying transient ocular hypertension exhibited by the primary PGs, the combination of the carbonic anhydrase inhibitor and the prostaglandin derivative can be used for the treatment of diseases and conditions in which the lowering of intraocular pressure 30 is desired, for example glaucoma, ocular hypertension and other disease accompanied by an increase in intraocular pressure. Thus, when a carbonic anhydrase inhibitor, which decreases the formation of aqueous humor, is combined with a prostaglandin or prostaglandin derivative, which increases the outflow of aqueous humor, WO 00/04899 PCT/US99/16374 -4 there is experienced an effect that reduces intraocular pressure below that obtained by either medicament individually. The activity of the carbonic anhydrase inhibitor currently marketed wanes 6 to 8 hours post-dose, meaning that as single agents 5 these carbonic anhydrase inhibitors must be administered at least three times day to maintain the desired lowering of intraocular pressure. The combination of this invention maintains the desired lowering of intraocular pessure for a full twelve hours. Because of this increased duration of action, the combination disclosed herein is 10 effective when administered only twice a day. Patient compliance is anticipated to be greater with twice a day administration than with three times a day administration. The combinations disclosed herein are effective either by co-administration of the medicaments in one solution or as a combined 15 therapy achieved by prior administration of either the carbonic anhydrase inhibitor or the prostaglandin derivative followed by administration of the other solution. The use of a single solution containing both active medicaments is preferred. There exists a patient population who will benefit from a 20 combination where the minimal dosage of one or both of the medicaments is employed, thus minimizing the possibility of the occurrence of undesirable effects of one or both of the medicaments which would be more likely to become apparent with chronic use at the higher dosage. 25 WO 00/04899 PCT/US99/16374 -5 SUMMARY OF THE INVENTION This invention relates to novel ophthalmic compositions comprising a topical carbonic anhydrase inhibitor or an ophthamologically acceptable salt thereof and a prostaglandin or 5 prostaglandin derivative thereof or a hypotensive lipid derived from a prostaglandin or prostaglandin derivative such as a PGF2a prostaglandin. In one aspect of the invention a composition comprising 0.025 to 5% (w/w) of a topical carbonic anhydrase inhibitor such as 5,6 10 dihydro-4-ethylamino-6-methyl-4H-thieno-[2,3-b]thiopyran-2 sulfonamide-7,7 dioxide hydrochloride or 2H-thieno[3,2-e]-1,2-thiazine 6-sulfonamide-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-1,1 dioxide and their trans and cis enantiomers, or an ophthalmologically acceptable salt thereof, including racemic material and 0.005 to 2% a 15 hypotensive lipid derived from prostaglandins and their trans and cis enantiomers, or an ophthalmologically acceptable salt thereof, including racemic material is disclosed. Said composition can optionally contain a gum belonging to the group consisting of gellan gum or xanthan gum. Another aspect of the invention is concerned with the use of 20 the novel ophthalmic compositions in the treatment of ocular hypertension or glaucoma.

WO 00/04899 PCT/US99/16374 -6 DETAILED DESCRIPTION OF THE INVENTION This invention relates to novel ophthalmic combinations comprising a topical carbonic anhydrase inhibitor or an ophthamologically acceptable salt thereof and a prostaglandin or 5 prostaglandin derivative thereof, or a topical carbonic anhydrase inhibitor or an ophthalmologically acceptable salt thereof and a hypotensive lipid derived from a prostaglandin or prostaglandin derivative, which are used in the treatment of ocular hypertension and glaucoma. 10 An aspect of this invention is realized when the prostaglandin is 11, 15-dipivaloyl PGF2a, 11 -pivaloyl prostaglandin F2a hydroxyethyl ester, (+)-(Z)-sodium-7-[lR, 2R, 3R, 5S)-3,5-dihydroxy-2-[(E)-1 15 octenyl]cyclopentyl]-5-heptenoate sesquihydrate, [la,2 ,3a,5ax]methyl-5-cis-2-(phenylethylsulfonanidomethyl)-3,5 dihydroxycyclopentyl heptenoate, (+-)-5-[6-(1 -hydroxy)hexyl)- 1,3-benzodioxol-5-yl]-pentanol, 15-pivaloyl PGFa, 20 7-[3a,5a dihydroxy-2-(3a-hydroxy-5--1E-pentenyl)cyclopentyl]-5Z heptenoic acid, isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5 phenylpentyl]cyclopentyl]-5-heptenoate, (+)-isopropyl fluprostenol; 25 [2R(1E, 3R),3S(4Z),4R]-isopropyl-7-(tetrahydro-2-[4-(3 chlorophenoxy)-3-hydroxy-1-butenyl)-4-hydroxy-3-furanyl]-4 heptanoate; 13,14-dihydro- 15(R)-i 7-phenyl- 18,19,20-trinor-PGF2a esters, 13,14-dihydro- 1 5-keto-20-ethyl-PGF 2 a isopropyl ester or 30 13,14-dihydro- 15 -keto-20-ethyl-PGF 2 a isopropyl ester trimethylphenol 1-acetate. Another aspect of this invention is realized when hypotensive lipids derived from PGF 2 a prostaglandins, in which the carboxylic acid group on the a-chain link of the basic prostaglandin WO 00/04899 PCT/US99/16374 -7 structure is replaced with electrochemically neutral substituents, is used. An example of a hypotensive lipid is that in which the carboxylic acid group is replaced with a C1-6 alkoxy group such as OCH 3 (PGF, 1

OCH

3 ), or a hydroxy group (PGF 2 a 1-OH). 5 A further aspect of this invention is realized when the prostaglandin is [2R(1E, 3R),3S(4Z),4R]-isopropyl-7-(tetrahydro-2-[4-(3 chlorophenoxy)-3-hydroxy-1-butenyl)-4-hydroxy-3-furanyl]-4 heptanoate; 10 (+)-isopropyl fluprostenol; or a hypotensive lipid derived from PGF2a prostaglandins and the topical carbonic anhydrase inhibitor is 5,6-dihydro-4-ethylamino-6 methyl-4H-thieno-[2,3-b]thiopyran-2-sulfonamide-7,7 dioxide hydrochloride or 2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-4 15 (ethylamino)-3,4-dihydro-2-(3-methoxypropyl)- 1,1-dioxide. Another embodiment of the invention is concerned with a novel ophthalmic composition comprising an ophthalmologically acceptable carrier, 0.025 to 5% (w/w) of a topical carbonic anhydrase 20 inhibitor, 5,6-dihydro-4-ethylamino-6-methyl-4H-thieno-[2,3 b]thiopyran-2-sulfonamide-7,7 dioxide hydrochloride, and its trans and cis enantiomers, or an ophthalmologically acceptable salt thereof, including racemic material and 0.005 to 2% (w/w) of a prostaglandin and its trans and cis enantiomers, or an ophthalmologically acceptable 25 salt thereof, including racemic material, wherein the prostaglandin is 11, 15-dipivaloyl PGF2a; (+)-isopropyl fluprostenol; or [2R(1E, 3R),3S(4Z),4R]-isopropyl-7-(tetrahydro-2-[4-(3-chlorophenoxy)-3 hydroxy-1-butenyl)-4-hydroxy-3-furanyl]-4-heptanoate. The term "prostaglandin or prostaglandin derivative", 30 within this invention refers to those naturally occurring prostaglandins that are useful for lowering intraocular pressure, specifically prostaglandins A,B,C,D,E,F and J class as well as synthetically modified prostaglandins including but not limited to 15-keto (oxo group in place WO 00/04899 PCT/US99/16374 -8 of OH at 15) 13,14-dihydro (single bond in place of double bond between positions 13 and 14), and esters thereof. Prostaglandins of the F class, particularly

PGF

2 , derivatives are known to be particularly potent at lowering intraocular 5 pressure. PGFa prostaglandin derived hypotensive lipids, in which the carboxylic acid group on the a-chain link of the basic prostaglandin structure is replaced with electrochemically neutral substituents, are also known to be particularly potent at lowering intraocular pressure. In particular, the hypotensive lipids intended for the claimed invention are 10 those compounds which increase aqueous humor outflow without any meaningful interaction with the FP prostaglandin receptor and little or no stimulation of the other prostanoid receptors (DP, EP1-4, IP, TP). Examples of such lipids are taught in US Patent Nos. 4,494,274; 5,034,413; 5,656,635; 5,516,791, 5,385,945, 5,688,819, 5,352,708 and 15 5,607978 all incorporated herein by reference. Although Formula I shows a basic skeleton having twenty carbon atoms, the prostaglandin compounds used in the present invention are not limited to those having the same number of carbon 10 atoms. The carbon atoms in Formula (I) are numbered 2 to 7 on the 20 (a-chain starting from the a-carbon atom adjacent to the carboxylic carbon atom which is numbered I and towards the five membered ring 8 to 12 on the ring starting from the carbon atom on which the a-chain is attached, and 13 to 20 on the o-chain starting from the carbon atom adjacent to the ring. When the number of carbon atoms is decreased on 25 the a-chain, the number is deleted in order starting from position 2 and when the number of carbon atoms is increased in the a-chain compounds are named as substituted derivatives having, substituents at position 1 in place of carboxy group at C-1. Similarly, when the number of carbon atoms is decreased in the o-chain, the number is 30 deleted in order starting from position 20 and when the number of carbon atoms is increased on the o-chain, compounds are named as substituted derivatives having respective substituent at position 20. Thus, 13,14-dihydro-15-keto-PG compounds having 10 carbon atoms in the o-chain are 13,14-dihydro-15-keto-20-ethyl PGs. The term WO 00/04899 PCT/US99/16374 -9 prostaglandin derivative also includes esters of the C-i carboxyl group, such as the C1-5 alkyl esters. The hypotensive lipids contemplated by the claimed invention include PGF 2 a lipid analogs which, unlike PGF 2 a,,, exhibit no 5 meaningful interaction with recombinant or constitutively expressed FP receptors (human, moust, cat). Further the PGF 2 a lipid analogs exhibit only either minimal or absent interaction with other prostanoid receptors (DP, EP, TP). Even with their inability to interact with with prostanoid receptors the subject PGF 2 a lipid analogs, having 10 electrochemically neutral substituents, are potent and efficacious at lowering elevated intraocular pressure (IOP). Examples of such lipids are taught in US Patent Nos. 4,494,274; 5,034,413; 5,656,635; 5,385,945, 5,688,819, 5,352,708 and 5,607978 all incorporated herein by reference. A particular ocular hypotensive agent is referred to as 15 AGN 192024, disclosed in VanDenburgh et al., Investigative Oph. and Vis. Sci. March 15, 1998, Vol. 39, No.4. p. S258 abstract 1177 and at the May 10-15, 1998 Association for Research in Vision and Ophthalmology (ARVO) meeting by Allergan of Irvine, California. The novel ophthalmic formulations of this invention 20 comprise about 0.025 to 5% (w/w) of the carbonic anhydrase inhibitors discussed herein, preferably 5,6-dihydro-4-ethylamino-6-methyl-4H thieno-[2,3-b]thiopyran-2-sulfonamide-7,7 dioxide hydrochloride or 2H thieno[3,2-e]-1,2-thiazine-6-sulfonamide-4-(ethylamino)-3,4-dihydro-2 (3-methoxypropyl)- 1,1-dioxide and their trans and cis enantiomers, or 25 an ophthalmologically acceptable salt thereof, including racemic material, usually about 0.5 to 3% (w/w) and more preferably about 0.7 to about 2% (w/w) and about 0.005 to 2.0% (w/w), preferably about 0.1 to 1% (w/w) of the prostaglandin or prostaglandin derivatives discussed herein, preferablys 13,14-dihydro-15(R)-17-phenyl-18,19,20-trinor 30 PGF2a esters or 13, 14-dihydro-15-keto-20-ethyl-PGF2a isopropryl esters, and more preferably isopropyl (Z)-7-[(iR,2R,3R,5S)-3,5 dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate, (+)-isopropyl fluprostenol, [2R(1E, 3R),3S(4Z),4R]-isopropyl-7 (tetrahydro-2-[4-(3-chlorophenoxy)-3-hydroxy- 1 -butenyl)-4-hydroxy- WO 00/04899 PCT/US99/16374 - 10 3-furanyl]-4-heptanoate; or 13,14-dihydro-15-keto-20-ethyl-PGF2a isopropyl ester trimethylphenol-1-acetate, to be administered on a 1 to 2 times a day schedule. A novel method of this invention comprises the topical 5 ocular administration of about 0.025 to about 5 mg per day, preferably about 0.25 to about 3 mg per day of a carbonic anhydrase inhibitor and concomitant, prior, or previous administration of about 0.005 to 2 mg per day, preferably about 0.1 to 1.0 mg per day, of prostaglandin or prostaglandin derivative to each eye. 10 Suitable subjects for the administration of the formulation of the present invention include mammals, primates, man, and other animals, particularly man and domesticated animals such as cats and dogs. For topical ocular administration the novel formulations of this invention may take the form of solutions, gels, ointments, suspensions or 15 solid inserts, formulated so that a unit dosage comprises a therapeutically effective amount of each active component or some submultiple thereof. Typical ophthalmologically acceptable carriers for the novel formulations are, for example, water, mixtures of water and 20 water-miscible solvents such as lower alkanols or aralkanols, vegetable oils, polyalkylene glycols, petroleum based jelly, ethyl cellulose, ethyl oleate, carboxymethylcellulose, polyvinylpyrrolidone, isopropyl myristate and other conventionally employed acceptable carriers. The pharmaceutical preparation may also contain non-toxic auxiliary 25 substances such as emulsifying, preserving, wetting agents, bodying agents and the like, as for example, polyethylene glycols 200, 300, 400 and 600, carbowaxes 1,000, 1,500, 4,000, 6,000 and 10,000, antibacterial components such as quaternary ammonium compounds, phenylmercuric salts known to have cold sterilizing properties and 30 which are non-injurious in use, thimerosal, benzalkonium chloride, methyl and propyl paraben, benzyldodecinium bromide, benzyl alcohol, phenylethanol, buffering ingredients such as sodium chloride, sodium borate, sodium acetate, or gluconate buffers, and other conventional ingredients such as sorbitan monolaurate, triethanolamine, WO 00/04899 PCTIUS99/16374 - 11 polyoxyethylene sorbitan monopalmitylate, dioctyl sodium sulfosuccinate, monothioglycerol, thiosorbitol, ethylenediamine tetra acetic acid, and the like. Additionally, suitable ophthalmic vehicles can be used as carrier media for the present purpose including conventional 5 phosphate buffer vehicle systems, isotonic boric acid vehicles, isotonic sodium chloride vehicles, isotonic sodium borate vehicles and the like. The formulation may also include a gum such as gellan gum at a concentration of 0.1% to 2% by weight so that the aqueous eyedrops gel on contact with the eye, thus providing the advantages of a solid 10 ophthalmic insert as described in U.S. Patent 4,861,760. The formulation may also include a gum such as xanthan gum at a concentration of 0.1 to 2%, preferably 0.4 to 0.7%(w/w). Particularly preferred is KELTROLTMT xanthan gum from Monsanto Performance Materials. The formulation of the instant invention 15 employing xanthan gum will be a hypotonic solution, with a freezing point depression between about -0.28'C and -0.4'C, and preferably between about -0.31'C and -0.37'C. Alternatively, the hypotonicity of the ophthalmic solutions of the present invention employing xanthan gum will be between about 150 and 215 mOs/kg, and preferably 20 between 170 and 200 mOs/kg. Coventional ophthalmic solutions are usually prepared as isotonic solutions using tonicity adjusting agents as potassium chloride, sodium chloride, mannitol, dextrose and glycerin. An isotonic solution will have a freezing point depression of approximately -0.54 C. Tonicity may also be measured by the 25 osmolality of the solution, an isotonic solution having an osmolality of about 290 milliosmoles per kilogram (mOs/kg). The pharmaceutical preparation may also be in the form of a solid insert such as one which after dispensing the drug remains essentially intact as described in U.S. Patents 4,256,108; 4,160,452; and 30 4,265,874; or a bio-erodible insert that either is soluble in lacrimal fluids, or otherwise disintegrates as described in U.S. Patent 4,287,175 or EPO publication 0,077,261. The pharmaceutical preparation may also be in the form of a suspension utilizing carbonic anhydrase inhibitors (CAl's) having WO 00/04899 PCT/US99/16374 - 12 aqueous solubilities greater than 10 gg/mL but less than 1000 pg/mL at pH 7.4, octanol/water distribution coefficients (DC) measured at pH 7.4 of from 1.0 to 150 and dissociation constants (Ki) of 1.0 nM or lower. The aqueous solubility is measured, for example, by mixing the CAI, in 5 its neutral or salt form in 0.1M phosphate buffer at a pH of 7.4. The mixture is then agitated for approximately 16 to 24 hours, while maintaining a pH of 7.4. If the mixture is a solution, a small amount of a seed crystal of the neutral CAI is added and the mixture is stirred for approximately 16 to 24 hours. The solid/liquid mixture is filtered 10 throught a 0.45 gm filter and the filtrated is assayed by HPLC against standards. The solubility as measured includes both the neutral and ionized forms of the CAI. Under these conditions, at pH 7.4, the CAI's employed for the suspension are predominantly unionized, with the possibility of 10 to 20% of the anionic sulfonamide present (depending 15 on the pKa of the primary sulfonamide group). By way of an example, the suspension encompassed within the meaning of this invention is one which comprises 0.1-10.9 wt% of a carbonic anhydrase inhibitor and 0.01-10.0 wt.% of a polyethoxylated derivative of castor oil resulting from the reaction of from 2-200 moles of ethylene oxide per 1 mole of 20 castor oil, wherein the derivatives can be hydrogenated. The measure of the dissociation constant is determined using the fluorescence competition assay which uses the fluorescent HCAII:dansylamide complex and is well known in the art, Chen et al., J. Biol. Chem., 242, 5813 (1967) and Ponticello et al., J. Med. Chem., 30, 25 591 (1987). The relative Kis for the suspension are less than 3.3 nM. The following examples of ophthalmic formulations are given by way of illustration and are not limitative of the invention. 30 WO 00/04899 PCT/US99/16374 - 13 EXAMPLE 1 SOLUTION COMPOSITION 1 11 111 (S,S)-(-)-5,6-dihydro-4-ethyl 5 amino-6-methyl-4H-thieno [2,3b]thiopyran-2-sulfonamide 7,7-dioxide monohydrochloride 22.26 g 22.26 g 1.113 g (carbonic anhydrase inhibitor) 10 (+)-isopropyl fluprostenol; (prostaglandin derivative) 10.0 g 1.0 g 1.0 g Sodium citrate.2H20 2.940 g 2.940 g 2.940 g 15 Benzalkonium Chloride 0.075 g 0.075 g 0.075 Hydroxyethylcellulose 5.00 g 5.00 g 5.00 g Sodium hydroxide q.s. pH = 6.0 pH = 6.0 pH = 6.0 20 Mannitol 16.00 g 21.00 g 35.90 g Water for injection q.s. ad. 1000 g 1000 g 1000 g 25 The active compounds, phosphate buffer salts, benzalkonium chloride, and Polysorbate 80 are added to and suspended or dissolved in water. The pH of the composition is adjusted to 5.5-6.0 and diluted 30 to volume. The composition is rendered sterile by 30 filtration through a sterilizing filter.

WO 00/04899 PCT/US99/16374 - 14 EXAMPLES 2-6 Following the procedures of Example 1, solutions are prepared substituting the compounds below for the carbonic anhydrase inhibitors: 5 Compound Example No. (S,S)-(-)-5,6-dihydro-4-ethyl- 2 amino-6-methyl-4H-thieno [2,3b]thiopyran-2-sulfonamide 10 7,7-dioxide (S,S)-(-)- 3,4-dihydro-4-ethylamino-2-methyl 2H-thieno[3,2-e]- 1,2-thiazine-6-sulfon- 3 amide-l,1-dioxide hydrochloride 15 R-(+)-3,4-dihydro-4-ethylamino-2 methyl-2H-thieno[3,2-e]-1,2- 4 thiazine-6-sulfonamide-1,1-dioxide hydrochloride 20 R-(+)-3,4-dihydro-4-ethylamino-2 (2-methoxy)ethyl-2H-thieno[3,2-e]-1,2- 5 thiazine-6-sulfonamide-1, 1-dioxide hydrochloride 25 (S,S)-(-)-5,6-dihydro-4-ethylamino- 6 6-propyl-4H-thieno[2,3b]thiopyran 2-sulfonamide-7,7-dioxide WO 00/04899 PCT/US99/16374 - 15 EXAMPLE 7(Suspension CONCENTRATION (WT/V%) R-(+)-4-ethylamino-3,4-dihydro-2-(3-methoxy) propyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 5 1,1-dioxide 2%+2% xs 13,14-dihydro- 15 -keto-20-ethyl PGF2. isopropyl ester (prostaglandin derivative) 0.5% 10 Hydroxypropylmethylcellulose 3% Dibasic Sodium Phosphate 0.2% 15 Sodium Chloride 0.7% Disodium Edetate 0.01% Polysorbate 80 0.05% 20 Benzalkonium Chloride 0.01% NaOH/HCl pH adjust 25 Purified Water q.s. 100% The suspension may be prepared by heating 400 mL of purified water to boiling. HPMC (30.0g) is added and the mixture stirred vigorously until homegeneous. To this is added a solution 30 consisting of sodium chloride (7.0 g), dibasic sodium phosphate (2.0g), disodium edta (0. lg), polysorbate 80 (0.5g) and benzalkonium chloride (10.5 mL of a 1% solution) and purified water is added to a final volume of 900 mL. The mixture is stirred and cooled in an ice bath to room temperature and the pH is adjusted to 7.2 employing HCI (3.5 mL WO 00/04899 PCT/US99/16374 - 16 of a 1 N solution. The mixture is q.s. to the final weight with purified water (total 1010g) and filtered through a 10 micron filter. The formulation is prepared by the addition of the above HPMC vehicle (15.014 g) to the above TCAI (0.3074 g) and prostaglandin (1.0 g) and 5 the mixture ias ball milled with 3 mm glass beads (5 g) for approximately 45 hours. EXAMPLES 8-15 Following the procedures of Example 1, solutions are 10 prepared substituting the compounds below for the prostaglandin derivative Compound Example No. 15 PGF2a,-l-isopropyl ester 8 PGA2 9 13,14-dihydro- 1 5-keto-PGE2 10 20 methyl ester 15-keto-PGF2x 11 25 PGF2a tromethamine salt 12 PGA1 13 (+)-isopropyl fluprostenol 14 30 [2R(1E, 3R),3S(4Z),4R]-isopropyl- 15 7-(tetrahydro-2-[4-(3-chlorophenoxy) 3-hydroxy- 1 -butenyl)-4-hydroxy-3 furanyl]-4-heptanoate; WO 00/04899 PCT/US99/16374 - 17 EXAMPLE 16 SOLUTION COMPOSITION I II 5,6-dihydro-4-ethylamino 5 6-methyl-4H-thieno[2,3b]thiopyran 2-sulfonamide-7,7-dioxide monohydrochloride 2.0 mg 0.2 mg (carbonic anhydrase inhibitor) 10 13,14-dihydro- 15-keto-20-ethyl PGF2a isopropyl ester trimethylphenol-1-acetate 0.1 mg 1.0 mg GelriteTM gellan gum 6.0 mg 6.0 mg 15 Monobasic sodium phosphate Quantity sufficient to give .2H20 Dibasic sodium phosphate final pH 5.5 - 6.0 20 .12H20 Benzyldodecinium bromide 0.10 mg 0.10 mg Polysorbate 80 0.2 mg 0.2 mg 25 Water for injection q.s. ad. 1.0 mL 1.0 mL The active compounds, Gelrite' gellan gum, phosphate buffer salts, benzyldodecinium bromide and Polysorbate 80 are added to 30 and suspended or dissolved in water. The pH of the composition is adjusted to 5.5-6.0 and diluted to volume. The composition is rendered sterile by ionizing radiation.

WO 00/04899 PCT/US99/16374 - 18 EXAMPLES 17-21 Following the procedures of Example 16, solutions are prepared substituting the compounds below for the carbonic anhydrase inhibitors: 5 Compound Example No. (S,S)-(-)-5,6-dihydro-4-ethylamino 6-methyl-4H-thien6[2,3b]thiopyran- 17 2-sulfonamide-7,7-dioxide 10 3,4-dihydro-4-ethylamino-2-methyl 2H-thieno[3,2-e]-1,2-thiazine-6-sulfon- 18 amide-1,1 dioxide hydrochloride 15 R-(+)-3,4-dihydro-4-ethylamino-2 methyl-2H-thieno[3,2-e]-1,2- 19 thiazine-6-sulfonamide-1,1-dioxide hydrochloride 20 R-(+)-3,4-dihydro-4-ethylamino-2- 20 (2-methoxy)ethyl-2H-thieno[3,2-e]- 1,2 thiazine-6-sulfonamide-1,1-dioxide hydrochloride 25 (S,S)-trans-5,6-dihidro-4-ethylamino- 21 6-propyl-4H-thieno[2,3b]thiopyran 2-sulfonamide-7,7- dioxide WO 00/04899 PCT/US99/16374 - 19 EXAMPLES 22-29 Following the procedures of Example 16, solutions are prepared substituting the compounds below for the prostaglandin 5 derivative. Compound Example PGF2a,-1-isopropyl ester 22 10 PGA2 23 13,14-dihydro-15-keto-PGE2 24 methyl ester 15 15-keto-PGF,2a 25 PGF2a tromethamine salt 26 PGA1 27 20 (+)-isopropyl fluprostenol; 28 [2R(1E, 3R),3S(4Z),4R]-isopropyl- 29 7-(tetrahydro-2-[4-(3-chlorophenoxy) 25 3-hydroxy-1-butenyl)-4-hydroxy-3 furanyl]-4-heptanoate; WO 00/04899 PCT/US99/16374 -20 EXAMPLE 30 SOLUTION COMPOSITION I II 5,6-dihydro-4-ethylamino 5 6-methyl-4H-thieno[2,3b]thiopyran 2-sulfonamide-7,7-dioxide monohydrochloride 2% 2% (carbonic anhydrase inhibitor) 10 13,14-dihydro-15-keto-20-ethyl PGF2a isopropyl ester trimethylphenol-l-acetate 0.1 % 1.0 % Xanthan gum 0.5% 0.7% 15 Sodium Chloride 0.2% 0.2% Benzalkonium Chloride 0.0075% 0.0075% 20 Sodium Hydroxide qs pH5.6 pH 5.6 Water qs 100% 100% The active compounds, sodium chloride and benzalkonium 25 chloride are dissolved in water for injection. The pH of the composition is adjusted to 5.6 by addition of 0.2N sodium hydroxide solution, and water for injection is added until the weight of the composition is equal to 75 parts of the final weight (I) or 65 parts of the final weight (II). The composition is sterilized by filtration, and the solution flushed with 30 sterile nitrogen. Then a clarified, steam sterilized concentrate of 2% xanthan gum is added to the solution of drug and the resulting solution is homogenized by stirring. The solution is aseptically subdivided into sterile vials and sealed.

WO 00/04899 PCT/US99/16374 - 21 EXAMPLES 31-35 Following the procedures of Example 30, solutions are prepared substituting the compounds below for the carbonic anhydrase 5 inhibitors: Compound Example No. (S,S)-(-)-5,6-dihydro-4-ethylamino 6-methyl-4H-thien6[2,3b]thiopyran- 31 10 2-sulfonamide-7,7-dioxide 3,4-dihydro-4-ethylamino-2-methyl 2H-thieno[3,2-e]-1,2-thiazine-6-sulfon- 32 amide-1,1 dioxide hydrochloride 15 R-(+)-3,4-dihydro-4-ethylamino-2 methyl-2H-thieno[3,2-e]-1,2- 33 thiazine-6-sulfonamide-1,1-dioxide hydrochloride 20 R-(+)-3,4-dihydro-4-ethylamino-2- 34 (2-methoxy)ethyl-2H-thieno[3,2-e]- 1,2 thiazine-6-sulfonamide-1,1-dioxide hydrochloride 25 (S,S)-trans-5,6-dihidro-4-ethylamino- 35 6-propyl-4H-thieno[2,3b]thiopyran 2-sulfonamide-7,7- dioxide 30 WO 00/04899 PCT/US99/16374 - 22 EXAMPLES 36-43 Following the procedures of Example 30, solutions are prepared substituting the compounds below for the prostaglandin 5 derivative. Compound Example PGF2u-l-isopropyl ester 36 10 PGA2 37 13,14-dihydro-15-keto-PGE2 38 methyl ester 15 15-keto-PGF,2a 39 PGF2c tromethamine salt 40 PGAI 41 20 (+)-isopropyl fluprostenol 42 [2R(1E, 3R),3S(4Z),4R]-isopropyl- 43 7-(tetrahydro-2-[4-(3-chlorophenoxy) 25 3-hydroxy- 1 -butenyl)-4-hydroxy-3 furanyl]-4-heptanoate;

Claims (14)

1. An ophthalmic formulation for the treatment of 5 ocular hypertension and glaucoma in a subject in need thereof, comprising an ophthalmologically acceptable carrier, 0.025 to 5% (w/w) of a topical carbonic anhydrase inhibitor or its trans and cis enantiomers, or an ophthalmologically acceptable salt thereof, including racemic material and 0.005 to 2% (w/w) of a hypotensive lipid derived 10 from a prostaglandin or prostaglandin derivative and their trans and cis enantiomers, or an ophthalmologically acceptable salt thereof, including racemic material.
2. The ophthalmic formulation according to claim 1 15 wherein the topical carbonic anhydrase inhibitor is 5,6-dihydro-4 ethylamino-6-methyl-4H-thieno-[2,3-b]thiopyran-2-sulfonamide-7,7 dioxide hydrochloride or 2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide
4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)- 1,1-dioxide and their trans and cis enantiomers, or an ophthalmologically acceptable salt 20 thereof, including racemic material. 3. The ophthalmic formulation according to claim 1 wherein the hypotensive lipid is derived from PGF 2 , prostaglandins. 25 4. A formulation according to claim 3 wherein the hypotensive lipid derived from PGF 2 prostaglandins contains electrochemically neutral substituents in place of the carboxylic acid group on the a-chain link of the basic prostaglandin structure. 30 5. The formulation of Claim 1 wherein the concentration of carbonic anhydrase inhibitor is 0.5% to 3% and the concentration of the hypotensive lipid is 0.1% to 1.0%. WO 00/04899 PCT/US99/16374 - 24 6. The formulation of claim 1 wherein the carbonic anhydrase inhibitor has an aqueous solubility greater than 10 ug/nL but less than 1000 ug/mL at pH 7.4, and a Ki of 1.0 nM or lower. 5 7. The formulation of claim 6 which is a suspension.
8. The formulation of claim 1 which optionally contains from about 0.1% to about 2% of gellan gum. 10 9. The formulation of claim 1 which optionally contains from about 0.1% to about 2% (w/w) of xanthan gum.
10. The formulation of claim 9 which contains from about 0.4 to about 0.7%(w/w) of xanthan gum, said xanthan gum being 15 a hypotonic solution, with a freezing point depression between about 0.28'C and -0.4'C.
11. The formulation of claim 10 wherein the gum is KELTROLTMT xanthan gum in a hypotonic solution with a freezing 20 point from about -0.31'C to about -0.37'C.
12. An ophthalmic formulation for the treatment of ocular hypertension and glaucoma in a subject in need thereof, comprising an ophthalmologically acceptable carrier, 0.5 to 3% (w/w) 25 of a topical carbonic anhydrase inhibitor or its trans and cis enantiomers, or an ophthalmologically acceptable salt thereof, including racemic material and 0.1 to 1.0% (w/w) of a hypotensive lipid derived from a prostaglandin or prostaglandin derivative and their trans and cis enantiomers, or an ophthalmologically acceptable salt thereof, including 30 racemic material and a gum belonging to the group consisting of from about 0.1 % to about 2% of gellan gum or from about 0.1% to about 2% (w/w) of xanthan gum.. WO 00/04899 PCTIUS99/16374 - 25 13. A formulation according to claim 12 wherein the carbonic anhydrase inhibitor is 5,6-dihydro-4-ethylamino-6-methyl-4H thieno-[2,3-b]thiopyran-2-sulfonamide-7,7 dioxide hydrochloride or 2H 5 thieno[3,2-e]-1, 2 -thiazine-6-sulfonamide-4-(ethylamino)-3,4-dihydro-2 (3-methoxypropyl)-1,1-dioxide and their trans and cis enantiomers, or an ophthalmologically acceptable salt thereof, including racemic material, the hypotensive lipid is derived from PGF 2 prostaglandins contains electrochemically neutral substituents in place of the carboxylic 10 acid group on the a-chain link of the basic prostaglandin structure and the gum is xanthan gum.
14. A formulation according to claim 13 which contains 15 from about 0.4 to about 0.7%(w/w) of xanthan gum, said xanthan gum being a hypotonic solution, with a freezing point depression between about -0.28'C and -0.4'C.
15. The formulation of claim 14 wherein the gum is 20 KELTROLTMT xanthan gum in a hypotonic solution with a freezing point from about -0.31'C to about -0.37'C.
16. An ophthalmic formulation for the treatment of ocular hypertension and glaucoma in a subject in need thereof, 25 comprising an ophthalmologically acceptable carrier, 0.025 to 5% (w/w) of a topical carbonic anhydrase inhibitor, 5,6-dihydro-4 ethylamino-6-methyl-4H-thieno-[2,3-b]thiopyran-2-sulfonamide-7,7 dioxide hydrochloride, and its trans and cis enantiomers, or an ophthalmologically acceptable salt thereof, including racemic material 30 and 0.005 to 2% (w/w) of a prostaglandin and its trans and cis enantiomers, or an ophthalmologically acceptable salt thereof, including racemic material, wherein the prostaglandin is 11, 15-dipivaloyl PGF2a; (+)-isopropyl fluprostenol; or [2R(1E, 3R),3S(4Z),4R]-isopropyl-7- WO 00/04899 PCTIUS99/16374 - 26 (tetrahydro-2-[4-(3-chlorophenoxy)-3-hydroxy- 1 -butenyl)-4-hydroxy 3-furanyl]-4-heptanoate.
17. A method of treating ocular hypertension and 5 glaucoma which comprises the topical ocular administration to a patient in need of such treatment of a unit dose of the formulation of Claim 1.
18. A method of treating ocular hypertension and glaucoma which comprises the topical ocular administration to a patient 10 in need of such treatment of a unit dose of the formulation of Claim 7.
19. A method of treating ocular hypertension and glaucoma which comprises the topical ocular administration to a patient in need of such treatment of a unit dose of the formulation of Claim 12. 15
20. A method of treating ocular hypertension and glaucoma which comprises the topical ocular administration to a patient in need of such treatment of a unit dose of the formulation of Claim 16.
AU51144/99A 1998-07-21 1999-07-20 Ophthalmic compositions for treating ocular hypertension Abandoned AU5114499A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11995198A true 1998-07-21 1998-07-21
US09119951 1998-07-21
PCT/US1999/016374 WO2000004899A1 (en) 1998-07-21 1999-07-20 Ophthalmic compositions for treating ocular hypertension

Publications (1)

Publication Number Publication Date
AU5114499A true AU5114499A (en) 2000-02-14

Family

ID=22387375

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51144/99A Abandoned AU5114499A (en) 1998-07-21 1999-07-20 Ophthalmic compositions for treating ocular hypertension

Country Status (5)

Country Link
EP (1) EP1100491A1 (en)
JP (1) JP2002521333A (en)
AU (1) AU5114499A (en)
CA (1) CA2337349A1 (en)
WO (1) WO2000004899A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754712B1 (en) * 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab ophthalmic compositions
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
WO2001085152A2 (en) * 2000-05-10 2001-11-15 Alcon, Inc. R-eliprodil for treating glaucoma
AU2002256471B2 (en) * 2001-05-03 2007-05-24 Allergan, Inc. Compositions having enhanced pharmacokinetic characteristics
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7939511B2 (en) 2004-09-28 2011-05-10 Senju Pharmaceutical Co., Ltd. Ophthalmic composition containing xanthan gum and amino acid
EP1911447B1 (en) 2005-07-11 2009-12-23 Senju Pharmaceutical Co., Ltd. Eye drop preparation comprising xanthan gum and terpenoid
GB2423711B (en) * 2005-10-24 2007-02-14 Fortune Apex Dev Ltd Method for preparing a pharmaceutical composition with enhanced mucoadhesion
KR101381035B1 (en) 2006-03-23 2014-04-04 센주 세이야꾸 가부시키가이샤 Ophthalmic composition comprising xanthan gum and glucose
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2146127C (en) * 1992-10-13 2000-06-13 Louis Desantis, Jr. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma

Also Published As

Publication number Publication date
JP2002521333A (en) 2002-07-16
EP1100491A1 (en) 2001-05-23
WO2000004899A1 (en) 2000-02-03
CA2337349A1 (en) 2000-02-03

Similar Documents

Publication Publication Date Title
CA2039420C (en) Treatment of cataract with 15-keto-prostaglandin compounds
US6646001B2 (en) Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
ES2317964T5 (en) Prostaglandin F2alpha derivative for the treatment of glaucoma or ocular hypertension
ES2355518T3 (en) Method and composition for the treatment of peripheral vascular diseases.
EP1514548B1 (en) A topical fluprostenol ophthalmic composition for the treatment of glaucoma and ocular hypertension
JP3719609B2 (en) Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and Mekyochi
EP0857718B1 (en) Endothelin antagonist
US5906989A (en) Cyclopentane(ENE) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
EP0664707B1 (en) Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
JP2592204B2 (en) Ocular hypotensive agents
EP1112106B1 (en) Serotonergic 5ht2 agonists for treating glaucoma
JP3631255B2 (en) Storage stability prostaglandin composition
US6342524B1 (en) Use of non-steroidal anti-inflammatory agents in combination with compounds that have FP prostaglandin agonist activity to treat glaucoma and ocular hypertension
EP1541151B1 (en) REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
US4883819A (en) Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
US6235781B1 (en) Prostaglandin product
JP4920124B2 (en) Compositions and methods for reducing ocular hypertension
US8017655B2 (en) Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
EP1392319B1 (en) Hypotensive lipid (prostaglandin) and timolol compositions and methods of using same
JP4275194B2 (en) Under ep ▲ as antiglaucoma agent 2 ▼ receptor agonist
US5151444A (en) Ocular hypotensive agents
US5688819A (en) Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US6184250B1 (en) Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
EP0561073B1 (en) Treatment of ocular hypertension with beta-blockers and derivatives of prostanoic acid
EP0242580A2 (en) Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted